Synexa Life Sciences
↗Leiden, Netherlands
Synexa Life Sciences is a leading specialist biomarker services company (CRO) that provides deep expertise in biomarker strategy, assay development, and clinical trial sample analysis. The company focuses on helping biopharma partners navigate the complexities of immunology, oncology, and infectious diseases through advanced analytical platforms.
Synexa operates a global network of laboratories and is known for its proprietary 'Proto-Type' platform, which allows for the analysis of complex immune responses. Following significant investment from GHO Capital, the company has aggressively expanded its capabilities through the acquisition of specialized labs like Syrinx Bioanalytics and Alderley Analytical, positioning itself as a premier mid-sized CRO in the biomarker space.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Contract Research Organization (CRO)
SIZE & FINANCIALS
Employees:51-200
Revenue:$25M-$50M
Founded:2003
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Total Raised:Unknown
Investors:GHO Capital Partners
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, mAb, Cell therapy, Gene therapy, Vaccines
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Syrinx Bioanalytics, Alderley Analytical
Key Partnerships:GHO Capital (Financial Partner), Various Tier 1 Pharma companies for biomarker validation
COMPETITION
Position:Niche Player
Competitors:Eurofins, Charles River Laboratories, Precision for Medicine, Labcorp Drug Development, Mercia Bio
LEADERSHIP
Key Executives:
Emile Lens - CEO
Justin Devine - Co-founder & Chief Medical Officer
Mark Reid - Chief Financial Officer
Scientific Founders:Justin Devine, Paul O'Riordan
Board Members:Alan MacKay (GHO Capital), Mike Gutch
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Synexa Life Sciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.